Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Letai

Cancer cell

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Cancer Cell|December 14, 2016
S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our QuiverAnthony Letai
Cancer Cell|November 14, 2006
Restoring cancer's death sentenceAnthony Letai
Cancer Cell|August 9, 2022
Precision medicine in AML: Function plus -omics is better than either aloneAnthony Letai
Cancer Cell|February 16, 2013
ABT-199: taking dead aim at BCL-2Matthew S Davids, Anthony Letai
Cancer Cell|December 24, 2021
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinationsAnthony Letai, Patrick Bhola, Alana L Welm
Cancer Cell|September 24, 2004
Antiapoptotic BCL-2 is required for maintenance of a model leukemiaAnthony Letai, Mia D Sorcinelli, Caroline Beard, et al.
Cancer Cell|August 19, 2007
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agentsJing Deng, Nicole Carlson, Kunihiko Takeyama, et al.
Cancer Cell|September 21, 2002
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeuticsAnthony Letai, Michael C Bassik, Loren D Walensky, et al.
Cancer Cell|May 16, 2006
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family membersMichael Certo, Victoria Del Gaizo Moore, Mari Nishino, et al.
Cancer Cell|November 16, 2005
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibDharminder Chauhan, Laurence Catley, Guilan Li, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Cancer Cell|December 14, 2016
S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our QuiverAnthony Letai
Cancer Cell|November 14, 2006
Restoring cancer's death sentenceAnthony Letai
Cancer Cell|August 9, 2022
Precision medicine in AML: Function plus -omics is better than either aloneAnthony Letai
Cancer Cell|February 16, 2013
ABT-199: taking dead aim at BCL-2Matthew S Davids, Anthony Letai
Cancer Cell|December 24, 2021
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinationsAnthony Letai, Patrick Bhola, Alana L Welm
Cancer Cell|September 24, 2004
Antiapoptotic BCL-2 is required for maintenance of a model leukemiaAnthony Letai, Mia D Sorcinelli, Caroline Beard, et al.
Cancer Cell|August 19, 2007
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agentsJing Deng, Nicole Carlson, Kunihiko Takeyama, et al.
Cancer Cell|September 21, 2002
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeuticsAnthony Letai, Michael C Bassik, Loren D Walensky, et al.
Cancer Cell|May 16, 2006
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family membersMichael Certo, Victoria Del Gaizo Moore, Mari Nishino, et al.
Cancer Cell|November 16, 2005
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibDharminder Chauhan, Laurence Catley, Guilan Li, et al.
Pageof 2